Company Performance: Novavax's financial health, including revenue, earnings, and profitability, significantly impacts its stock price. Positive earnings reports typically lead to price increases, while losses can cause declines.

Clinical Trial Results: The success or failure of Novavax's clinical trials for its vaccines and other products heavily influences investor sentiment and stock valuation. Positive results drive optimism and higher prices; negative results do the opposite.

Regulatory Approvals: Approval of Novavax's vaccines by regulatory bodies like the FDA or EMA is a major catalyst for stock price increases. Conversely, delays or rejections negatively affect the stock.

Market Sentiment: Overall market conditions and investor sentiment towards the biotechnology sector can affect Novavax's stock. Bull markets tend to lift all stocks, while bear markets depress prices.

Competition: The competitive landscape in the vaccine market, particularly from larger players like Pfizer and Moderna, influences Novavax's market share and potential revenue, impacting its stock price.

News and Events: News related to Novavax, such as partnerships, acquisitions, or major announcements, can cause volatility in the stock price.

Economic Factors: Macroeconomic factors like interest rates, inflation, and economic growth can affect investor confidence and overall market valuations, impacting NVX.US.

Global Health Crises: Outbreaks of infectious diseases or pandemics can significantly increase demand for Novavax's vaccines, driving up its stock price.

Production Capacity: Novavax's ability to manufacture and distribute its vaccines at scale is crucial for meeting demand and generating revenue, affecting stock performance.

Government Contracts: Securing contracts with governments to supply vaccines provides revenue certainty and positively influences investor confidence in Novavax's future prospects, boosting stock value.